{"id":"NCT01723904","sponsor":"UCB BIOSCIENCES GmbH","briefTitle":"A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease","officialTitle":"An Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3B","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2013-03","completion":"2013-04","firstPosted":"2012-11-08","resultsPosted":"2014-06-03","lastUpdate":"2014-06-03"},"enrollment":90,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Advanced Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"Rotigotine","otherNames":["Neupro"]}],"arms":[{"label":"Rotigotine","type":"EXPERIMENTAL"}],"summary":"This study is to investigate the safety and efficacy of Rotigotine add-on therapy with low doses of Pramipexole or Ropinirole in patients with advanced-stage Parkinson's Disease (PD) who have insufficient response to L-dopa and low doses dopamine receptor agonists.","primaryOutcome":{"measure":"Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period","timeFrame":"Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)","effectByArm":[{"arm":"Rotigotine","deltaMin":61,"sd":null}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":22,"countries":["Australia","Malaysia","Singapore","South Korea","Taiwan"]},"refs":{"pmids":["25879416"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":90},"commonTop":["Application site pruritus","Dizziness","Orthostatic hypotension","Nausea","Dyskinesia"]}}